Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE
NCT00326898Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2006
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of sunitinib, sorafenib in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Apr 2006; status: completed.
02
Drugs
sunitinibsorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00326898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326898.